Background: The diagnosis of chronic lymphocytic leukemia (CLL) is mainly based on blood count, morphology, and immunophenotyping. In Indonesia, the diagnosis is more challenging as the availability of immunophenotyping tests is limited. The European Society of Medical Oncology (ESMO) stated flowcytometry as a prerequisite to establishing diagnosis of CLL, meanwhile in the original International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria, which has been widely accepted by physicians caring for patients with CLL,  the diagnosis of CLL can be made in patients with cytopenia using bone marrow biopsy where flowcytometry test is not available. The aim of the study was to compare the utility of International Workshop on Chronic Lymphocytic Leukemia 2018 [iwCLL 2018 (2)] compared with National Cancer Institute Working Group 96 (NCI-WG96) criteria in the diagnosis of CLL in Indonesia, especially in limited resource settings.

Methods: The data of newly diagnosed CLL patients, including baseline demographic, clinical, and laboratory characteristics was retrieved retrospectively from medical records in Cipto Mangunkusumo General Hospital from 2015 until 2021. Diagnosis of CLL  using iwCLL 2018 diagnostic criteria were then compared with National Cancer Institute Working Group 96 (NCI-WG96) criteria.  Results: Thirty-eight patients were enrolled to this study. The median age was 59.5 years and dominated by males. Most of them were classified in the late-stage disease (63.4% in Binet C and about 70% in Rai III-IV). Four cases were CD5-negative CLL. Based on NCI-WG96 guideline, only 24 patients (63.2%) fulfilled all four criteria for CLL. Similarly, using the iwCLL 2018 flowcytometric criteria without biopsy data, 26 patients (68%) were diagnosed as CLL.   However, if bone marrow biopsy in patient with cytopenia was taken into account, all patients (100%) can be confirmed as CLL.

Conclusion: The iwCLL 2018 criteria which included bone marrow biopsy in the presence of cytopenia was more applicable to establish the diagnosis of CLL in Indonesia where flowcytometry is not available.

Download full-text PDF

Source

Publication Analysis

Top Keywords

iwcll 2018
20
chronic lymphocytic
16
lymphocytic leukemia
16
diagnosis cll
16
bone marrow
12
marrow biopsy
12
diagnosis
8
diagnosis chronic
8
leukemia iwcll
8
2018 compared
8

Similar Publications

Clinical trials in early-stage CLL: what has been learned and what's next?

Leuk Lymphoma

November 2024

Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany.

More than 80% of newly diagnosed chronic lymphocytic leukemia (CLL) patients present with asymptomatic, early-stage CLL. Of these, only 30-50% progress to advanced stage with reduced survival, while the rest may never require treatment. According to the 2018 International Workshop on CLL (iwCLL) guidelines, patients who do not meet the criteria for treatment initiation should only be treated within the context of clinical trials, as data demonstrating an overall survival benefit in early-stage CLL are still awaited.

View Article and Find Full Text PDF

Background: The diagnosis of chronic lymphocytic leukemia (CLL) is mainly based on blood count, morphology, and immunophenotyping. In Indonesia, the diagnosis is more challenging as the availability of immunophenotyping tests is limited. The European Society of Medical Oncology (ESMO) stated flowcytometry as a prerequisite to establishing diagnosis of CLL, meanwhile in the original International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria, which has been widely accepted by physicians caring for patients with CLL,  the diagnosis of CLL can be made in patients with cytopenia using bone marrow biopsy where flowcytometry test is not available.

View Article and Find Full Text PDF

Patients with chronic lymphocytic leukemia (CLL) with disease progression on ibrutinib have worse outcomes compared to patients stopping ibrutinib due to toxicity. A better understanding of expected outcomes in these patients is necessary to establish a benchmark for evaluating novel agents currently available and in development. We evaluated outcomes of 144 patients with CLL treated at Mayo Clinic with 2018 iwCLL disease progression on ibrutinib.

View Article and Find Full Text PDF

To report the efficacy, safety, and quality of life (QoL) on generic and innovator ibrutinib in Indian CLL patients. This was a single centre, prospective study of treatment-naive (TN), and relapsed/refractory (R/R) CLL patients receiving ibrutinib in India. The choice of innovator or generic ibrutinib was as per patient discretion.

View Article and Find Full Text PDF
Article Synopsis
  • A pilot study evaluated the concurrent use of ibrutinib with CD19 CAR T-cell therapy in 19 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) after failing ibrutinib treatment.
  • The combination therapy was safe and well tolerated, with 68% of patients receiving planned ibrutinib doses and an impressive overall response rate of 83%.
  • Patients demonstrated a high rate of minimal residual disease (MRD)-negative responses, and the treatment was associated with reduced severity of cytokine release syndrome (CRS) compared to CAR T-cell therapy alone.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!